NeuroOne stockholders approve 2025 Equity Incentive Plan and reverse stock split

NEUROONE MEDICAL TECHNOLOGIES Corp

Approved 2025 Equity Incentive Plan authorizing up to 3M new shares plus returning shares from prior plan.
Approved reverse stock split at ratio of 1:2 to 1:15, with exact ratio to be set by the Board.
David Rosa re-elected as Class II director with 11.7M votes for, 381.7K withheld, 6.0M broker non-votes.
Ratified Baker Tilly U.S., LLP as independent auditor for FY2025 with 18.1M votes for, 7.4K against.
Adjournment proposal also approved, with 16.8M votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.